In conclusion, our findings suggest that CD109 deficiency plays a role in suppression of the mutation rate of the H-ras gene in the early phase of DMBA/TPA-induced skin tumorigenesis by enhancing the TGF-β/p21/Nrf2 pathway, and significantly reduces the number and size of papillomas. The gene discussed is HRAS; the disease is papilloma.